Height as a risk factor in meningioma: a study of 2 million Israeli adolescents.
Allergy
Autoimmune disease
Height
Meningioma
Sex
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
20 Aug 2020
20 Aug 2020
Historique:
received:
23
04
2020
accepted:
11
08
2020
entrez:
22
8
2020
pubmed:
21
8
2020
medline:
15
4
2021
Statut:
epublish
Résumé
Meningiomas are the most common primary central nervous system tumors. Potential risk factors include obesity, height, history of allergy/atopy, and autoimmune diseases, but findings are conflicting. This study sought to assess the role of the different risk factors in the development of meningioma in adolescents/young adults. The cohort included 2,035,915 Jewish men and women who had undergone compulsory physical examination between 1967 and 2011, at age 16 to 19 years, prior to and independent of actual military enlistment. To determine the incidence of meningioma, the military database was matched with the Israel National Cancer Registry. Cox proportional hazard models were used to estimate the hazard ratios for meningioma according to sex, body mass index (BMI), height, and history of allergic or autoimmune disease. A total of 480 subjects (328 females) were diagnosed with meningioma during a follow-up of 40,304,078 person-years. Median age at diagnosis was 42.1 ± 9.4 years (range 17.4-62.6). On univariate analysis, female sex (p < 0.01) and height (p < 0.01) were associated with risk of meningioma. When the data were stratified by sex, height remained a significant factor only in men. Spline analysis of the male subjects showed that a height of 1.62 m was associated with a minimum disease risk and a height of 1.85+ meters, with a significant risk. This large population study showed that sex and adolescent height in males (> 1.85 m) were associated with an increased risk of meningioma in adulthood.
Sections du résumé
BACKGROUND
BACKGROUND
Meningiomas are the most common primary central nervous system tumors. Potential risk factors include obesity, height, history of allergy/atopy, and autoimmune diseases, but findings are conflicting. This study sought to assess the role of the different risk factors in the development of meningioma in adolescents/young adults.
METHODS
METHODS
The cohort included 2,035,915 Jewish men and women who had undergone compulsory physical examination between 1967 and 2011, at age 16 to 19 years, prior to and independent of actual military enlistment. To determine the incidence of meningioma, the military database was matched with the Israel National Cancer Registry. Cox proportional hazard models were used to estimate the hazard ratios for meningioma according to sex, body mass index (BMI), height, and history of allergic or autoimmune disease.
RESULTS
RESULTS
A total of 480 subjects (328 females) were diagnosed with meningioma during a follow-up of 40,304,078 person-years. Median age at diagnosis was 42.1 ± 9.4 years (range 17.4-62.6). On univariate analysis, female sex (p < 0.01) and height (p < 0.01) were associated with risk of meningioma. When the data were stratified by sex, height remained a significant factor only in men. Spline analysis of the male subjects showed that a height of 1.62 m was associated with a minimum disease risk and a height of 1.85+ meters, with a significant risk.
CONCLUSIONS
CONCLUSIONS
This large population study showed that sex and adolescent height in males (> 1.85 m) were associated with an increased risk of meningioma in adulthood.
Identifiants
pubmed: 32819306
doi: 10.1186/s12885-020-07292-4
pii: 10.1186/s12885-020-07292-4
pmc: PMC7441683
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
786Références
Neuro Oncol. 2012 Nov;14(11):1316-24
pubmed: 22952197
Cancer Prev Res (Phila). 2011 Sep;4(9):1385-92
pubmed: 21685234
Cancer Causes Control. 2011 Oct;22(10):1355-63
pubmed: 21710191
Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95
pubmed: 16331155
Diabetes Care. 2014 Nov;37(11):2982-8
pubmed: 25092683
Br J Cancer. 2016 Jun 28;115(1):108-14
pubmed: 27253176
J Neurol Sci. 2020 Jan 15;408:116552
pubmed: 31756667
J Natl Cancer Inst. 2007 Oct 17;99(20):1544-50
pubmed: 17925535
Acta Oncol. 2017 Oct;56(10):1302-1309
pubmed: 28548875
Int J Cancer. 2002 May 10;99(2):252-9
pubmed: 11979441
Lancet. 1974 Feb 23;1(7852):277-9
pubmed: 4130470
J Neurooncol. 2010 Jul;98(3):379-84
pubmed: 20013146
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
Neurology. 2015 Oct 13;85(15):1342-50
pubmed: 26377253
Neuro Oncol. 2011 Sep;13(9):1011-9
pubmed: 21750006
Cancer Detect Prev. 2005;29(5):440-7
pubmed: 16188400
J Clin Endocrinol Metab. 2004 Jan;89(1):213-8
pubmed: 14715852
Mol Pathol. 2001 Aug;54(4):227-9
pubmed: 11477136
Eur J Epidemiol. 2009;24(8):433-40
pubmed: 19484497
Ann Hum Biol. 2011 Mar;38(2):194-202
pubmed: 20731527